DA Davidson Issues Pessimistic Estimate for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Equities research analysts at DA Davidson lowered their Q1 2025 EPS estimates for shares of USANA Health Sciences in a research report issued to clients and investors on Thursday, February 27th. DA Davidson analyst C. Xue now expects that the company will post earnings of $0.76 per share for the quarter, down from their prior estimate of $0.83. DA Davidson has a “Neutral” rating and a $36.00 price target on the stock. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. DA Davidson also issued estimates for USANA Health Sciences’ Q1 2025 earnings at $0.76 EPS, FY2025 earnings at $2.38 EPS, FY2025 earnings at $2.38 EPS and FY2026 earnings at $2.59 EPS.

A number of other equities analysts have also commented on the stock. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 14th. Sidoti downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

USANA Health Sciences Stock Down 14.0 %

USNA stock opened at $28.57 on Friday. The stock has a 50-day simple moving average of $33.50 and a two-hundred day simple moving average of $36.56. USANA Health Sciences has a twelve month low of $27.71 and a twelve month high of $50.32. The firm has a market capitalization of $544.54 million, a PE ratio of 10.10, a PEG ratio of 0.93 and a beta of 0.87.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.15. The company had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%.

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently modified their holdings of USNA. R Squared Ltd bought a new position in shares of USANA Health Sciences in the fourth quarter worth approximately $28,000. Safe Harbor Fiduciary LLC purchased a new position in USANA Health Sciences in the 3rd quarter worth approximately $30,000. KBC Group NV grew its stake in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock worth $40,000 after buying an additional 519 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of USANA Health Sciences in the 4th quarter worth $83,000. Finally, Quantbot Technologies LP purchased a new stake in shares of USANA Health Sciences during the 4th quarter valued at $132,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.